Author:
Lotz J-P, ,Pautier P,Selle F,Viens P,Fabbro M,Lokiec F,Viret F,Gligorov J,Gosse B,Provent S,Ribrag V,Micléa J-M,Dosquet C,Goetschel A,Cailliot C,Lefèvre G,Genève J,Lhommé C
Publisher
Springer Science and Business Media LLC
Subject
Transplantation,Hematology
Reference35 articles.
1. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334: 1–6.
2. Trimble EL, Adams JD, Vena D, Hawkins MJ, Friedman MA, Fisherman JS et al. Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103. J Clin Oncol 1996; 11: 2405–2410.
3. Karlan BY, Markman MA, Eifel PJ . Ovarian cancer, fallopian tube carcinoma, and peritoneal carcinoma. In: De Vita Jr VT, Hellman S, Rosenberg SA (eds). Cancer: Principles and Practice in Oncology, 7th edn. Lippincott Williams & Wilkins: Philadelphia, PA, 2005, pp 1364–1388.
4. ten Bokkel Huinink W, Lane SR, Ross GA, International Topotecan Study Group. Long-term survival in a phase III, randomized study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma. Ann Oncol 2004; 15: 100–103.
5. Gordon AN, Tonda M, Sun S, Rackoff W, Doxil Study 30–49 Investigators. Long-term survival advantage for women treated with pegylated liposomial doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol 2004; 95: 1–8.
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献